Wayground logo

Free Printable Worksheets

Font size

S
M
L
XL
Worksheets

Day 1 Morning Session

Total questions: 9

Worksheet time: 7mins

Name
Class
Date
1.

Which of the following statements regarding to the Declaration of Helsinki are TRUE?

a)

Is developed by World Medical Association

b)

Is applicable to interventional studies but not to studies on identifiable human samples

c)

Has been updated multiple times

2.

Clinical trials should be conducted

a)

in accordance with Declaration of Geneva

b)

in GCP-compliant manner

c)

in accordance with the Declaration of Helsinki

d)

prior to protocol review by IRB/IEC

3.

The following statements are based on the Malaysian Guideline for Good Clinical Practice EXCEPT

a)

It details the conduct of epidemiological studies

b)

The principles are in keeping with the Declaration of Helsinki

c)

The information on Investigational product should be fully available to the investigator

d)

The delegated study coordinator should be qualified by education, training and experience

4.

The independent Ethic committee have the following responsibilities EXCEPT

a)

Obtain Curriculum Vitae (CV) of Investigators.

b)

Safeguarding investigator right and safety

c)

Review investigator qualifications

d)

Keep records 3 years after trial completion

5.

Choose the correct statements

It is recommended by ICH GCP that IRB/IEC should include:

a)

at least 5 members

b)

at least one member whose primary area of interest is in a non-scientific area

c)

at least one member whose area of specialty is religious affair

d)

at least one member who is independent of the institution / trial site

6.

How frequently does ICH require the investigator to submit reports to the Ethics Committee

a)

It doesn’t-it’s the sponsor responsibility

b)

Annually

c)

At the end of trial

d)

The frequency is not specified

7.

Protocol is a document that describe the (a)   , design, methodology, statistical consideration and organisation of a trial.

8.

The following should be included in the clinical trial protocol EXCEPT

a)

Description of the population to be studied

b)

Compensation to the PI

c)

Direct access to source data/document

d)

Trial objectives and purpose

9.

The following information should be included in the Investigator’s Brochure to address the effects in humans:

a)

Information on pharmacokinetics

b)

Dose response

c)

Pharmaceutical data

d)

Safety, efficacy and pharmacological activities